Sanofi Cares North America directs virtually all recorded giving toward ensuring access to prescription medicines for vulnerable patients, funding large-scale free drug and patient assistance programs. The foundation’s grants appear to be corporate philanthropic support of medication access and distribution rather than broad community or arts funding. Its visible giving is highly programmatic and tied to direct patient support services for ill, needy, or infant populations.
Extremely concentrated: very few, very large gifts directed to patient assistance/drug provision programs (repeat funding for the same programmatic purpose). Funding is program-specific and operational rather than fragmented across many small grantees.
Sanofi Cares North America Formerly the Sanofi Foundation for N America is defined by large-scale support for free prescription drugs and patient assistance, with recorded grants directed to ill, needy, and infant patients. The largest listed grant, $4,149,829,881 in 2025, went to a recipient name withheld in the source record and was earmarked to provide free drugs to those patients. A 2023 grant of $1,798,841,615 to Atch 4 in Bridgewater, NJ carried the same purpose, showing a repeated pattern of product-based support rather than general operating philanthropy. The foundation’s visible giving is highly programmatic: its active grant programs center on access to healthcare through Sanofi Patient Connection and related patient assistance product donations, along with targeted support for infant and pediatric needs. It also maintains disaster-relief and humanitarian-aid partnerships that can move medicines and medical supplies through established relief organizations during emergencies.
Access to medicines is the clearest throughline in the foundation’s grant history. In 2025, it awarded $4,149,829,881 to a recipient listed as Hippa Regulations Prevent the Listing of Names (Various, NJ) to provide free drugs to ill, needy, or infant patients. A second grant in 2023 sent $1,798,841,615 to Atch 4 (Bridgewater, NJ) for the same purpose. Beyond direct patient access, the foundation runs a diabetes camps drug donation program that provides donated insulin for children age 18 and under attending accredited camps in the United States and U.S. territories. It also supports disaster relief and humanitarian aid partnerships, including emergency medicines and medical supplies delivered through established partner organizations.
The recorded grants are unusually concentrated in a single size band: the p25, median, and p75 are all $1,798,841,615. That suggests a very small set of very large awards rather than a broad spread of smaller grants. The two listed recent grants also show repetition of purpose across years, both framed as free-drug support for ill, needy, or infant patients. The funder is a regular funder, not a DAF, and it does not fund individuals or make program-related investments. One active program, the diabetes camps donation process, accepts unsolicited applications.
$4.1B
$0
$4.1B
$4.1B
Most grants fall between $1.8B and $1.8B, with a median of $1.8B.
25th Percentile
$1.8B
Median
$1.8B
75th Percentile
$1.8B
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Notable grantees: HIPPA REGULATIONS PREVENT THE LISTING OF NAMES (patient assistance/free drug provision), ATCH 4 (patient assistance/free drug provision), Unspecified corporate patient assistance program(s) for medication access
Grantmaking is entirely localized in the available record: 100% of grants went to recipients in New Jersey. The top state by grant count is NJ, which also matches the headquarters state. Named recipient locations include Bridgewater, NJ and another New Jersey recipient with a redacted name. Program geography is broader in some active areas, including the United States and U.S. territories for diabetes camps, and U.S. plus international coverage for disaster-response partnerships, but the listed grants themselves land in New Jersey.
Its recorded grants focus on access to prescription medicines, especially free-drug support for ill, needy, or infant patients. The active program list also includes patient assistance product donations through Sanofi Patient Connection and related channels.
The available grant-size distribution is extremely concentrated: p25, median, and p75 are all $1,798,841,615. The two recent grants shown are both in the billion-dollar range.
All listed grants go to New Jersey recipients, and New Jersey is also the top state by grant count. The geography shown in the recipient country distribution is 100% US.
Yes for some programs. The diabetes camps drug donation program accepts unsolicited applications, and the access-to-healthcare patient assistance program is listed as accepting unsolicited requests. Disaster relief partnerships are handled through established partner organizations.
The recent grants are directed to New Jersey recipients and are described as providing free drugs to ill, needy, or infant patients. One recipient is listed as Atch 4 in Bridgewater, NJ; the other is redacted in the source record.
2025
Source: IRS Form 990-PF, fiscal year 2025.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| HIPPA REGULATIONS PREVENT THE LISTING OF NAMES | VARIOUS, NJ | $4,149,829,881 | 2025 | TO PROVIDE FREE DRUGS TO ILL, NEEDY OR INFANT PATIENTS. |
| ATCH 4 | BRIDGEWATER, NJ | $2,973,990,875 | 2024 | TO PROVIDE FREE DRUGS TO ILL, NEEDY OR INFANT PATIENTS. |
| ATCH 4 | BRIDGEWATER, NJ | $1,798,841,615 | 2023 | TO PROVIDE FREE DRUGS TO ILL, NEEDY OR INFANT PATIENTS. |
HIPPA REGULATIONS PREVENT THE LISTING OF NAMES
$4,149,829,881TO PROVIDE FREE DRUGS TO ILL, NEEDY OR INFANT PATIENTS.
ATCH 4
$2,973,990,875TO PROVIDE FREE DRUGS TO ILL, NEEDY OR INFANT PATIENTS.
ATCH 4
$1,798,841,615TO PROVIDE FREE DRUGS TO ILL, NEEDY OR INFANT PATIENTS.